{"doi":"10.1158/2159-8290.cd-21-0450","title":"Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study","abstract":"High tumor mutational burden (TMB-H) correlates with improved immunotherapy response. We assessed atezolizumab 1,200 mg every 3 weeks for TMB-H tumors from MyPathway (NCT02091141), a phase IIa multibasket study. One hundred twenty-one patients had advanced solid tumors with TMB ≥10 mut/Mb by any Clinical Laboratory Improvement Amendments (CLIA)-certified assay. The preplanned primary endpoint was objective response rate (ORR) in patients with TMB ≥16 mut/Mb tumors by FoundationOne TMB testing [F1(CDx)]. Patients with F1(CDx) TMB ≥10 and <16 mut/Mb were also evaluated. Ninety patients with 19 tumor types and F1(CDx) TMB ≥10 mut/Mb were efficacy evaluable. In 42 patients with F1(CDx) TMB ≥16 mut/Mb, confirmed ORR was 38.1% [16/42; 95% confidence interval (CI), 23.6-54.4], and disease control rate was 61.9% (26/42; 95% CI, 45.6-76.4) versus 2.1% (1/48; 95% CI, 0.1-11.1) and 22.9% (11/48; 95% CI, 12.0-37.3) for 48 patients with TMB ≥10 and <16 mut/Mb. Responses were observed in nine different tumor types (47%; 9/19). SIGNIFICANCE: Atezolizumab monotherapy had promising, durable clinical activity across a variety of advanced solid tumor types in patients with TMB ≥16 mut/Mb tumors lacking other suitable treatment options and who were immunotherapy-naïve at enrollment, regardless of microsatellite instability status. Limited activity was observed in tumors with TMB ≥10 and <16 mut/Mb. See related commentary by Maron and Klempner, p. 602. This article is highlighted in the In This Issue feature, p. 587.","journal":"Cancer Discovery","year":2021,"id":149837,"datarank":2.9939808743851377,"base_score":4.624972813284271,"endowment":4.624972813284271,"self_citation_contribution":0.6937459219926407,"citation_network_contribution":2.300234952392497,"self_endowment_contribution":0.6937459219926407,"citer_contribution":2.300234952392497,"corpus_percentile":null,"corpus_rank":null,"citation_count":101,"citer_count":89,"citers_with_citation_signal":67,"citers_with_endowment":67,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8963,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02091141"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":44889,"name":"John D. Hainsworth","orcid":"0000-0002-2848-6546","position":1,"is_corresponding":false},{"id":108759,"name":"Razelle Kurzrock","orcid":"0000-0003-4110-1214","position":2,"is_corresponding":false},{"id":1539,"name":"David R. Spigel","orcid":"0000-0003-3215-9465","position":3,"is_corresponding":false},{"id":289289,"name":"Howard A. Burris","orcid":"0000-0002-1501-2931","position":4,"is_corresponding":false},{"id":342648,"name":"Christopher J. Sweeney","orcid":"0000-0002-0398-6018","position":5,"is_corresponding":false},{"id":70220,"name":"Funda Meric‐Bernstam","orcid":"0000-0001-6816-6072","position":6,"is_corresponding":false},{"id":636931,"name":"Yong Wang","orcid":"0000-0003-4707-5280","position":7,"is_corresponding":false},{"id":636932,"name":"Jonathan Levy","orcid":"0000-0001-8055-8888","position":8,"is_corresponding":false},{"id":636933,"name":"Jessica M. Grindheim","orcid":"0000-0003-2149-1622","position":9,"is_corresponding":false},{"id":614828,"name":"David S. Shames","orcid":"0000-0002-5900-1177","position":10,"is_corresponding":false},{"id":619213,"name":"Katja Schulze","orcid":"0000-0003-3704-5651","position":11,"is_corresponding":false},{"id":379105,"name":"Arisha Patel","orcid":"0000-0002-2396-5222","position":12,"is_corresponding":false},{"id":80131,"name":"Charles Swanton","orcid":"0000-0002-4299-3018","position":13,"is_corresponding":false},{"id":381100,"name":"Claire F. Friedman","orcid":"0000-0003-2621-8553","position":0,"is_corresponding":true}],"reference_count":38,"raw_metadata":null,"created_at":"2026-07-18T23:42:56.251607Z","pmid":"34876409","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}